JP2015511632A5 - - Google Patents

Download PDF

Info

Publication number
JP2015511632A5
JP2015511632A5 JP2015502543A JP2015502543A JP2015511632A5 JP 2015511632 A5 JP2015511632 A5 JP 2015511632A5 JP 2015502543 A JP2015502543 A JP 2015502543A JP 2015502543 A JP2015502543 A JP 2015502543A JP 2015511632 A5 JP2015511632 A5 JP 2015511632A5
Authority
JP
Japan
Prior art keywords
melanoma
trifluoromethyl
amino
treatment
raf inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015502543A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015511632A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2013/052556 external-priority patent/WO2013144923A1/en
Publication of JP2015511632A publication Critical patent/JP2015511632A/ja
Publication of JP2015511632A5 publication Critical patent/JP2015511632A5/ja
Pending legal-status Critical Current

Links

JP2015502543A 2012-03-30 2013-03-29 メラノーマの治療におけるｒａｆ阻害剤およびｍｅｋ阻害剤の投与 Pending JP2015511632A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261618006P 2012-03-30 2012-03-30
US61/618,006 2012-03-30
PCT/IB2013/052556 WO2013144923A1 (en) 2012-03-30 2013-03-29 Administration of a raf inhibitor and a mek inhibitor in the treatment of melanoma

Publications (2)

Publication Number Publication Date
JP2015511632A JP2015511632A (ja) 2015-04-20
JP2015511632A5 true JP2015511632A5 (enExample) 2016-06-02

Family

ID=48326371

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015502543A Pending JP2015511632A (ja) 2012-03-30 2013-03-29 メラノーマの治療におけるｒａｆ阻害剤およびｍｅｋ阻害剤の投与

Country Status (6)

Country Link
US (1) US20150126533A1 (enExample)
EP (1) EP2830664A1 (enExample)
JP (1) JP2015511632A (enExample)
CN (1) CN104428001A (enExample)
CA (1) CA2868954A1 (enExample)
WO (1) WO2013144923A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3068393T (pt) 2013-11-11 2022-06-14 Amgen Inc Terapia de combinação, incluindo um inibidor de mdm2 e um ou mais agentes farmaceuticamente ativos adicionais para o tratamento de cancros
UY36046A (es) * 2014-03-26 2015-10-30 Millennium Pharm Inc Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
CA2972076A1 (en) * 2014-12-23 2016-06-30 Millennium Pharmaceuticals, Inc. Combination of raf inhibitors and aurora kinase inhibitors
US20190117652A1 (en) * 2014-12-23 2019-04-25 Millennium Pharmaceuticals, Inc. Combination of raf inhibitors and taxanes
WO2017066664A1 (en) * 2015-10-16 2017-04-20 Millennium Pharmaceuticals, Inc. Combination therapy including a raf inhibitor for the treatment of colorectal cancer
WO2017165491A1 (en) * 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Use of a pd-1 antagonist and a raf inhibitor in the treatment of cancer
US11395823B2 (en) 2018-01-09 2022-07-26 Duke University Topical administration of MEK inhibiting agents for the treatment of skin disorders
CN115023230A (zh) * 2019-11-27 2022-09-06 首日生物制药公司 泛raf激酶抑制剂的固体分散体
JP2023548600A (ja) * 2020-11-06 2023-11-17 デイ ワン バイオファーマシューティカルズ， インコーポレイテッド 低グレード神経膠腫を処置するためのｒａｆインヒビター
CN117042772A (zh) * 2020-11-06 2023-11-10 首日生物制药公司 用于治疗低级别胶质瘤的raf抑制剂
CN117177754A (zh) * 2021-02-19 2023-12-05 首日生物制药公司 Raf抑制剂和mek抑制剂的组合
MX2023009642A (es) * 2021-02-19 2023-10-16 Day One Biopharmaceuticals Inc Combinacion de inhibidor de raf e inhibidor de mek.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2985B1 (ar) * 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
WO2008120004A1 (en) * 2007-04-02 2008-10-09 Astrazeneca Ab Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer
TWI444379B (zh) * 2007-06-29 2014-07-11 Sunesis Pharmaceuticals Inc 有用於作為Ｒａｆ激酶抑制劑之化合物
JO3101B1 (ar) * 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
ES2745479T3 (es) * 2009-10-16 2020-03-02 Novartis Ag Combinación que comprende un inhibidor de MEK y un inhibidor de B-raf
WO2012145503A1 (en) * 2011-04-21 2012-10-26 Novartis Ag Pharmaceutical combinations

Similar Documents

Publication Publication Date Title
JP2015511632A5 (enExample)
UA113157C2 (xx) Спосіб лікування з використанням селективних інгібіторів bcl-2
PE20151091A1 (es) Agentes inductores de apoptosis para el tratamiento de cancer y enfermedades inmunes y autoinmunes
JP2012530705A5 (enExample)
EP3641754A4 (en) Sleep disorder compositions and treatments thereof
NO2017023I1 (no) Venetoklaks, dvs. 4-(4-{[2-(4-klorfenyl)-4,4-dimetylsykloheks-1-en-1-yl]metyl}piperazin-1-yl)-N-({3-nitro-4[{tetrahydro-2H-pyran-4-ylmetyl)amino]fenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloksy)benzamid
ZA201101891B (en) The salts of n-[4-(1-cyanocyclopentyl)phenyl]-2-(4-pyridyl methyl)amino-3-pyridinecarboxamide
AR116394A2 (es) Mesilato de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida monohidrato
CN110139865A (zh) Fgfr抑制剂
PE20170705A1 (es) Nuevos compuestos como inhibidores de ret (reorganizado durante la transfeccion)
JP2012517962A5 (enExample)
HRP20170638T1 (hr) MODULATORI RETINOIDNIMA SRODNOG SIROČETA RECEPTORA γ (ROR-γ), NAMIJENJENI UPOTREBI U LIJEČENJU AUTOIMUNIH I PROTUUPALNIH BOLESTI
JP2014062126A5 (enExample)
BR112017004673A2 (pt) formas cristalinas de 2-(4-(4-etoxi-6-oxo-1,6-diidropiridin-3-ila)-2-fluorofenil)-n-(5-(1,1,1-trifluoro-2-metilpropan-2-il)isoxazol-3-il) acetamida
PL2684877T3 (pl) Faramceutycznie dopuszczalna sól (e)-n-[4-[[3-chloro-4-(2-pirydylometoksy)fenylo]amino]-3-cyjano-7-etoksy-6-chinolilo]-3-[(2r)-1-metylopirolidyn-2-ylo]prop-2-enamidu, sposób jej otrzymywania i jej medyczne zastosowanie
LT3544976T (lt) N-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamido laisvos bazės hemihidratas, jo gamybos būdai ir panaudojimai
JP2013538856A5 (enExample)
PL3544977T3 (pl) Sól maleinianowa wolnej zasady n-[5-(aminosulfonylo)-4-metylo-1,3-tiazol-2-ilo]-n-metylo-2-[4-(2-pirydynylo)fe¬nylo]acetamidu, preparaty farmaceutyczne, sposoby wytwarzania oraz ich zastosowania do leczenia wirusa opryszczki
MX2019001007A (es) Uso novedoso de nectinib y una sal farmaceuticamente aceptable del mismo en el tratamiento contra enfermedades.
EP3643708C0 (en) 2-[4-(METHYLAMINOMETHYL)PHENYL]-5-FLUORO-BENZOFURAN-7-CARBOXAMIDE HYDROCHLORIDE POLYMORPH, ITS PREPARATION PROCESS AND APPLICATION
JP2015509917A5 (enExample)
AU2023903757A0 (en) Use of 2-(3-fluoro-4-(trifluoromethyl)phenyl)-N-(2-(1-hydroxypropan-2-yl)-6-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)acetamide in the treatment of cardiovascular diseases
CN302063839S (zh) 平板电脑支架（具散热性能）
CN302545738S (zh) 档案包（健康档案）
CN302299186S (zh) 声音重放设备